<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055743</url>
  </required_header>
  <id_info>
    <org_study_id>2009PHC001</org_study_id>
    <nct_id>NCT01055743</nct_id>
  </id_info>
  <brief_title>The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma</brief_title>
  <official_title>A Randomized, Controlled Trial of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Simcere Pharmaceutical Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Simcere Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the clinical efficacy and safety of fluorouracil implants regional
      chemotherapy during the surgical treatment for early-stage hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the clinical benefit of fluorouracil implants regional chemotherapy during the radical resection in early stage hepatocellular carcinoma patients. The primary endpoint is disease-free survival (DFS).</measure>
    <time_frame>1, 2, and 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>from baseline to the last visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Complications</measure>
    <time_frame>1, 2, and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from the beginning of treatment to the end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Early Stage Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radical resection + Fluorouracil Implants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radical resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical resection</intervention_name>
    <description>Radical resection of hepatocellular carcinoma</description>
    <arm_group_label>Radical resection + Fluorouracil Implants</arm_group_label>
    <arm_group_label>Radical resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil Implants</intervention_name>
    <description>Implanted during the surgical treatment</description>
    <arm_group_label>Radical resection + Fluorouracil Implants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of stage I hepatocellular carcinoma

          -  Child-Pugh class A, B

          -  Radical resection is feasible

          -  Patients with adequate renal, hepatic, and hematologic function

          -  Written informed consent

        Exclusion Criteria:

          -  Allergic to chemotherapy drugs

          -  No measurable lesion

          -  Receive chemotherapy, radiotherapy or biotherapy within 30 days prior to enrollment

          -  Evidence of serious infection

          -  Renal or hepatic dysfunction, significant cardiovascular disease

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuqun Cheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuqun Cheng, MD</last_name>
    <phone>86-021-81875251</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuqun Cheng, MD</last_name>
      <phone>86-021-81875251</phone>
    </contact>
    <investigator>
      <last_name>Shuqun Cheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2010</study_first_posted>
  <last_update_submitted>January 24, 2010</last_update_submitted>
  <last_update_submitted_qc>January 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shuqun Cheng</name_title>
    <organization>Eastern Hepatobiliary Surgery Hospital</organization>
  </responsible_party>
  <keyword>Fluorouracil Implants</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Radical resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

